GM1ガングリオシドーシス治療の世界市場：製品タイプ別、疾患タイプ別、地域別 - 規模、シェア、展望、機会分析（2022年～2028年）

世界のGM1ガングリオシドーシス治療市場では、主要企業がプレゼンスを高めるために、戦略的協定に注力しています。

当レポートでは、世界のGM1ガングリオシドーシス治療市場について調査分析し、市場促進要因と抑制要因、市場機会、COVID-19の影響、製品タイプ・疾患タイプ・地域別の市場分析、競合情勢などを提供しています。

目次

第1章 調査目的・前提条件

第2章 市場の範囲

• レポートの説明
• 市場の定義と範囲
• エグゼクティブサマリー
• 市場スナップショット：製品タイプ別
• 市場スナップショット：疾患タイプ別
• 市場スナップショット：地域別
• Coherent Opportunity Map (COM)

第3章 市場力学・規制・動向分析

• 促進要因
• 抑制要因
• 市場機会
• 影響分析
• パイプライン分析
• 規制シナリオ
• 重要な開発
• 疫学
• 1次調査の洞察
• 患者の洞察
• 医師の洞察
• メーカーの洞察

第4章 世界のGM1ガングリオシドーシス治療市場：COVID-19流行の影響

• 経済的影響
• 疫学におけるCOVID-19
• 進行中の臨床試験に対するCOVID-19の影響

第5章 世界のGM1ガングリオシドーシス治療市場：製品タイプ別（2017年～2028年）

• イントロダクション
• 市場シェア分析
• 前年比成長率分析
• セグメント動向

第6章 世界のGM1ガングリオシドーシス治療市場：疾患タイプ別（2017年～2028年）

• イントロダクション
• 市場シェア分析
• 前年比成長率分析
• セグメント動向

第7章 世界のGM1ガングリオシドーシス治療市場：地域別（2017年～2028年）

• イントロダクション
• 北米
• 欧州
• その他の地域

第8章 競合情勢

• 企業プロファイル
• Axovant Gene Therapies Ltd.
• Passage Bio
• Lysogene

GM1 gangliosidosis is a progressive neurological genetic disorder mainly caused by the absence of a vital enzyme known as beta-galactosidase (GLB1). Without GLB1, a fatty substance called GM1 gangliosidosis accumulates in cells, and nerve cells of the brain. GM1 gangliosidosis is one of the 50 genetically inherited disorders known as lysosomal storage diseases. Currently, there is no treatment or cure for treatment of GM1 gangliosidosis.

Market Dynamics

Key players are focusing on strategic agreements in order to expand their presence in the market. For instance, in May 2017, Lysogene entered a strategic manufacturing agreement with Brammer Bio, a viral gene and cell therapy manufacturer. The agreement is expected to help Brammer Bio manufacture LYS-GM101, an AAVrh10- based gene therapy for the treatment of GM1 gangliosidosis.

Key features of the study:

• This report studies the current scenario as well as the future potential of the global GM1 gangliosidosis market. The market for GM1 gangliosidosis is segmented on the basis of product type, disease type, and region.
• This report provides in-depth analysis of the global GM1 gangliosidosis market, and provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
• It profiles leading players in the global GM1 gangliosidosis market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, key developments, and future plans
• Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansion and marketing tactics
• The global GM1 gangliosidosis market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
• Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global GM1 gangliosidosis market

Detailed Segmentation:

• Global GM1 Gangliosidosis Treatment Market, By Product Type :
  • LYS-GM101
  • PBGM01
  • AXO-AAV-GM1
• Global GM1 Gangliosidosis Treatment Market, By Disease Type :
  • Type 1 GM1 Gangliosidosis
  • Type 2 GM1 Gangliosidosis
  • Type 3 GM1 Gangliosidosis
• Global GM1 Gangliosidosis Treatment Market, By Region:
  • North America
    • By Product Type:
    • LYS-GM101
    • PBGM01
    • AXO-AAV-GM1
    • By Disease Type :
    • Type 1 GM1 Gangliosidosis
    • Type 2 GM1 Gangliosidosis
    • Type 3 GM1 Gangliosidosis
    • By Country:
    • U.S.
    • Canada
  • Europe
    • By Product Type:
    • LYS-GM101
    • PBGM01
    • AXO-AAV-GM1
    • By Disease Type :
    • Type 1 GM1 Gangliosidosis
    • Type 2 GM1 Gangliosidosis
    • Type 3 GM1 Gangliosidosis
    • By Country:
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Rest of World
    • By Product Type:
    • LYS-GM101
    • PBGM01
    • AXO-AAV-GM1
    • By Disease Type :
    • Type 1 GM1 Gangliosidosis
    • Type 2 GM1 Gangliosidosis
    • Type 3 GM1 Gangliosidosis
    • By Region:
    • Latin America
    • Asia Pacific
    • Middle East
    • Africa.
• Company Profiles.
  • Axovant Gene Therapies Ltd. *
    • Company Overview
    • Material Portfolio
    • Financial Performance
    • Key Highlights
    • Market Strategies
  • Passage Bio
  • Lyosgene

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
• Market Definition and Scope
• Executive Summary
• Market Snapshot, By Product Type
• Market Snapshot, By Disease Type
• Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Drivers
• Restraints
• Market Opportunities
• Impact Analysis
• Pipeline Analysis
• Regulatory Scenario
• Key Development
• Epidemiology
• Primary Research Insights
• Patient Insights
• Physician Insights
• Manufacturer Insights

4. Global GM1 Glangliosidosis Treatment Market - Impact of COVID-19 Pandemic

• Economic Impact
• COVID-19 Epidemiology
• Impact of COVID-19 on Ongoing Clinical Trials

5. Global GM1 Glangliosidosis Treatment Market, By Product Type, 2017 - 2028 (US$ Mn)

• Introduction
• Market Share Analysis, 2022 and 2028 (%)
• Y-o-Y Growth Analysis, 2017 - 2028
• Segment Trends
  • LYS-GM101
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • PBGM01
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • AXO-AAV-GM1
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

6. Global GM1 Glangliosidosis Treatment Market, By Disease Type, 2017 - 2028 (US$ Mn)

• Introduction
• Market Share Analysis, 2022 and 2028 (%)
• Y-o-Y Growth Analysis, 2017 - 2028
• Segment Trends
  • Type 1 GM1 Gangliosidosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Type 2 GM1 Gangliosidosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Type 3 GM1 Gangliosidosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

7. Global GM1 Glangliosidosis Treatment Market, By Region, 2017 - 2028 (US$ Mn)

• Introduction
• Market Share Analysis, By Country, 2022 and 2028 (%)
• Y-o-Y Growth Analysis, For Countries, 2017 - 2028
• North America
• Introduction
• Market Size and Forecast, By Product Type, 2017 - 2028 (US$ Mn)
• Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
• Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • U.S.
  • Canada
• Europe
• Introduction
• Market Size and Forecast, By Product Type, 2017 - 2028 (US$ Mn)
• Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
• Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Rest of World
• Introduction
• Market Size and Forecast, By Product Type, 2017 - 2028 (US$ Mn)
• Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
• Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
  • Latin America
  • Asia Pacific
  • Middle East
  • Africa.

8. Competitive Landscape

• Company Profiles
• Axovant Gene Therapies Ltd.
• Company Overview
• Clinical Trial Phase Portfolio
• Financial Overview
• Key Highlights
• Market Strategies
• Passage Bio
• Company Overview
• Clinical Trial Phase Portfolio
• Financial Overview
• Key Highlights
• Market Strategies
• Lysogene
• Company Overview
• Clinical Trial Phase Portfolio
• Financial Overview
• Key Highlights
• Market Strategies